Uvette Lou
YOU?
Author Swipe
View article: A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma Open
View article: 323 | A PROSPECTIVE ANALYSIS OF THE SAFETY AND EFFICACY OF PROPHYLACTIC DEXAMETHASONE FOR GLOFITAMAB ADMINISTRATION IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
323 | A PROSPECTIVE ANALYSIS OF THE SAFETY AND EFFICACY OF PROPHYLACTIC DEXAMETHASONE FOR GLOFITAMAB ADMINISTRATION IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA Open
View article: Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study
Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study Open
View article: Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Open
Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-world study to evaluate Ven-O in r/r CLL/SL…
View article: Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH
Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH Open
Purpose Data on the optimal management of patients with hematologic malignancies and chemotherapy-induced nausea and vomiting (CINV) are lacking. We report our institutional experience in patients with B-cell lymphoma receiving multiday do…
View article: The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm Open
Background Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the…
View article: The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil–Associated Coronary Vasospasm Open
View article: Issue Information
Issue Information Open
Aims and Scope: For more than 50 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacolog…
View article: Effect of Levetiracetam on Time to High‐Dose Methotrexate Clearance in Patients With Hematologic Malignancies
Effect of Levetiracetam on Time to High‐Dose Methotrexate Clearance in Patients With Hematologic Malignancies Open
High‐dose methotrexate (HDMTX) is a commonly used treatment for hematologic malignancies involving the central nervous system. Two case reports described possible delayed methotrexate clearance in patients receiving concurrent levetiraceta…
View article: Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia
Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia Open
Introduction Guidelines recommend pegfilgrastim for primary prophylaxis of febrile neutropenia after highly myelosuppressive chemotherapy. While deviations from guidelines could result in overuse and increased costs, underuse is also a con…